Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar pchop123 (79.74) Submitted: 1/23/2013 4:05:16 PM : Outperform Start Price: $2.99 PGNX Score: -4.48

has sustaining power

Featured Broker Partners


Advertisement